Inogen (NASDAQ:INGN) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Inogen, Inc (NASDAQ:INGN) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.17 and traded as low as $6.15. Inogen shares last traded at $6.23, with a volume of 194,339 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Inogen presently has an average rating of “Hold” and a consensus price target of $11.00.

Inogen Trading Up 0.2%

The stock has a market capitalization of $169.64 million, a P/E ratio of -7.24 and a beta of 1.77. The stock’s fifty day moving average price is $6.16 and its two-hundred day moving average price is $7.17.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company had revenue of $81.72 million for the quarter, compared to analyst estimates of $82.00 million. Inogen had a negative net margin of 6.52% and a negative return on equity of 11.56%. As a group, analysts expect that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new stake in shares of Inogen in the 2nd quarter valued at about $4,668,000. CSM Advisors LLC bought a new position in Inogen during the 3rd quarter worth approximately $2,973,000. Divisadero Street Capital Management LP increased its stake in Inogen by 192.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 455,389 shares of the medical technology company’s stock worth $3,201,000 after purchasing an additional 299,571 shares during the period. GSA Capital Partners LLP purchased a new position in Inogen in the 3rd quarter worth approximately $1,397,000. Finally, Goldman Sachs Group Inc. lifted its position in Inogen by 37.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 589,273 shares of the medical technology company’s stock valued at $3,960,000 after purchasing an additional 160,960 shares during the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.